Frontiers in Oncology (Apr 2021)
Pleural Fluid Has Pro-Growth Biological Properties Which Enable Cancer Cell Proliferation
- Rachelle Asciak,
- Rachelle Asciak,
- Rachelle Asciak,
- Nikolaos I. Kanellakis,
- Nikolaos I. Kanellakis,
- Nikolaos I. Kanellakis,
- Nikolaos I. Kanellakis,
- Xuan Yao,
- Xuan Yao,
- Megat Abd Hamid,
- Megat Abd Hamid,
- Rachel M. Mercer,
- Maged Hassan,
- Eihab O. Bedawi,
- Melissa Dobson,
- Peter Fsadni,
- Stephen Montefort,
- Tao Dong,
- Tao Dong,
- Najib M. Rahman,
- Najib M. Rahman,
- Najib M. Rahman,
- Najib M. Rahman,
- Ioannis Psallidas,
- Ioannis Psallidas,
- Ioannis Psallidas
Affiliations
- Rachelle Asciak
- Oxford Centre for Respiratory Medicine, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
- Rachelle Asciak
- Laboratory of Pleural and Lung Cancer Translational Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Rachelle Asciak
- Mater Dei Hospital, Msida, Malta
- Nikolaos I. Kanellakis
- Oxford Centre for Respiratory Medicine, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
- Nikolaos I. Kanellakis
- Laboratory of Pleural and Lung Cancer Translational Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Nikolaos I. Kanellakis
- National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom
- Nikolaos I. Kanellakis
- Chinese Academy of Medical Sciences Oxford Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Xuan Yao
- Chinese Academy of Medical Sciences Oxford Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Xuan Yao
- MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
- Megat Abd Hamid
- Chinese Academy of Medical Sciences Oxford Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Megat Abd Hamid
- MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
- Rachel M. Mercer
- Oxford Centre for Respiratory Medicine, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
- Maged Hassan
- Oxford Centre for Respiratory Medicine, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
- Eihab O. Bedawi
- Oxford Centre for Respiratory Medicine, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
- Melissa Dobson
- Oxford Respiratory Trials Unit, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Peter Fsadni
- Mater Dei Hospital, Msida, Malta
- Stephen Montefort
- Mater Dei Hospital, Msida, Malta
- Tao Dong
- Chinese Academy of Medical Sciences Oxford Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Tao Dong
- MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
- Najib M. Rahman
- Oxford Centre for Respiratory Medicine, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
- Najib M. Rahman
- Laboratory of Pleural and Lung Cancer Translational Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Najib M. Rahman
- National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom
- Najib M. Rahman
- Oxford Respiratory Trials Unit, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Ioannis Psallidas
- Oxford Centre for Respiratory Medicine, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
- Ioannis Psallidas
- Laboratory of Pleural and Lung Cancer Translational Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Ioannis Psallidas
- Research and Early Development, Respiratory & Immunology, AstraZeneca, Cambridge, United Kingdom
- DOI
- https://doi.org/10.3389/fonc.2021.658395
- Journal volume & issue
-
Vol. 11
Abstract
ObjectivesPatients with malignant pleural mesothelioma (MPM) or pleural metastases often present with malignant pleural effusion (MPE). This study aimed to analyze the effect of pleural fluid on cancer cells.Materials and MethodsEstablished patient-derived cancer cell cultures derived from MPE (MPM, breast carcinoma, lung adenocarcinoma) were seeded in 100% pleural fluid (exudate MPM MPE, transudate MPE, non-MPE transudate fluid) and proliferation was monitored. In addition, the establishment of new MPM cell cultures, derived from MPE specimens, was attempted by seeding the cells in 100% MPE fluid.ResultsAll established cancer cell cultures proliferated with similar growth rates in the different types of pleural fluid. Primary MPM cell culture success was similar with MPE fluid as with full culture medium.ConclusionsPleural fluid alone is adequate for cancer cell proliferation in vitro, regardless of the source of pleural fluid. These results support the hypothesis that pleural fluid has important pro-growth biological properties, but the mechanisms for this effect are unclear and likely not malignant effusion specific.
Keywords
- pleural fluid
- malignant pleural effusion (MPE)
- pleural metastases
- malignant pleural mesothelioma
- pleural cancer
